CDKN2B and myelodysplastic syndrome: The DNA demethylation agent arsenic trioxide was able to restore the expression of methylation-silenced CDKN2B in the human T lymphoblast cell line Molt4 and human myelodysplastic syndrome-(MDS-REBT) cell line Mutz-1 [72], indicating the potential of DNA demethylation agents to contribute to cancer treatment in some instances.